Academic Journal
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer.
| Title: | Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer. |
|---|---|
| Authors: | Yu QX; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China., Fu PY; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China., Zhang C; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China., Li L; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China., Huang WT; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China. huangwt@cicams.ac.cn. |
| Source: | World journal of gastrointestinal surgery [World J Gastrointest Surg] 2024 May 27; Vol. 16 (5), pp. 1395-1406. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101532473 Publication Model: Print Cited Medium: Print ISSN: 1948-9366 (Print) NLM ISO Abbreviation: World J Gastrointest Surg Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing, China : Baishideng |
| Abstract: | Background: Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer-related mortality worldwide. Mesenchymal-epithelial transition factor (MET) gene participates in multiple tumor biology and shows clinical potential for pharmacological manipulation in tumor treatment. MET amplification has been reported in CRC, but data are very limited. Investigating pathological values of MET in CRC may provide new therapeutic and genetic screening options in future clinical practice. Aim: To determine the pathological significance of MET amplification in CRC and to propose a feasible screening strategy. Methods: A number of 205 newly diagnosed CRC patients undergoing surgical resection without any preoperative therapy at Shenzhen Cancer Hospital of Chinese Academy of Medical Sciences were recruited. All patients were without RAS/RAF mutation or microsatellite instability-high. MET amplification and c-MET protein expression were analyzed using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. Correlations between MET aberration and pathological features were detected using the chi-squared test. Progression free survival (PFS) during the two-year follow-up was detected using the Kaplan-Meier method and log rank test. The results of MET FISH and IHC were compared using one-way ANOVA. Results: Polysomy-induced MET amplification was observed in 14.4% of cases, and focal MET amplification was not detected. Polysomy-induced MET amplification was associated with a higher frequency of lymph node metastasis (LNM) (P < 0.001) and higher tumor budding grade (P = 0.02). In the survival analysis, significant difference was detected between patients with amplified- and non-amplified MET in a two-year follow-up after the first diagnosis (P = 0.001). C-MET scores of 0, 1+, 2+, and 3+ were observed in 1.4%, 24.9%, 54.7%, and 19.0% of tumors, respectively. C-MET overexpression correlated with higher frequency of LNM (P = 0.002), but no significant difference of PFS was detected between patients with different protein levels. In terms of concordance between MET FISH and IHC results, MET copy number showed no difference in c-MET IHC 0/1+ (3.35 ± 0.18), 2+ (3.29 ± 0.11) and 3+ (3.58 ± 0.22) cohorts, and the MET-to-CEP7 ratio showed no difference in three groups (1.09 ± 0.02, 1.10 ± 0.01, and 1.09 ± 0.03). Conclusion: In CRC, focal MET amplification was a rare event. Polysomy-induced MET amplification correlated with adverse pathological characteristics and poor prognosis. IHC was a poor screening tool for MET amplification. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Competing Interests: | Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose. |
| References: | Nat Rev Clin Oncol. 2021 Feb;18(2):101-115. (PMID: 32901132) J Thorac Oncol. 2018 Dec;13(12):1962-1967. (PMID: 30149144) J Pers Med. 2021 Dec 14;11(12):. (PMID: 34945842) J Thorac Oncol. 2016 Aug;11(8):1293-1304. (PMID: 27262212) Ann Oncol. 2017 Dec 01;28(12):3009-3014. (PMID: 29045518) JAMA. 2004 Apr 28;291(16):1972-7. (PMID: 15113815) Exp Ther Med. 2021 Dec;22(6):1480. (PMID: 34765021) Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. (PMID: 32514147) Histopathology. 2002 Feb;40(2):127-32. (PMID: 11952856) Lancet Respir Med. 2023 Jul;11(7):624-636. (PMID: 37156249) Histopathology. 1981 Mar;5(2):141-63. (PMID: 7216178) J Thorac Oncol. 2017 Jan;12(1):15-26. (PMID: 27794501) J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. (PMID: 34663410) Biomedicines. 2015 Jan 22;3(1):71-88. (PMID: 28536400) Cancer Res Treat. 2020 Apr;52(2):481-491. (PMID: 31645095) Oncotarget. 2016 Aug 23;7(34):54627-54631. (PMID: 27421137) Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19. (PMID: 22128289) Cancer Discov. 2020 Jul;10(7):922-934. (PMID: 32532746) World J Gastroenterol. 2015 Mar 28;21(12):3706-10. (PMID: 25834339) Expert Opin Ther Targets. 2021 Apr;25(4):249-268. (PMID: 33945380) ESMO Open. 2021 Dec;6(6):100319. (PMID: 34837746) Cancer Lett. 2008 Jul 8;265(2):258-69. (PMID: 18395971) Mol Diagn Ther. 2022 Mar;26(2):203-227. (PMID: 35266116) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) J Pathol Transl Med. 2020 Jan;54(1):34-44. (PMID: 31693827) J Thorac Oncol. 2019 Sep;14(9):1666-1671. (PMID: 31228623) J Gastrointest Oncol. 2021 Oct;12(5):2203-2210. (PMID: 34790385) Mod Pathol. 2017 Sep;30(9):1299-1311. (PMID: 28548122) Am J Surg Pathol. 2008 Dec;32(12):1816-21. (PMID: 18779725) Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. (PMID: 18093943) Hum Pathol. 2018 Jul;77:108-115. (PMID: 29641976) Cancer Cell. 2003 Apr;3(4):347-61. (PMID: 12726861) Mod Pathol. 2000 Nov;13(11):1238-43. (PMID: 11106082) Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. (PMID: 22128285) Lung Cancer. 2012 Jan;75(1):89-94. (PMID: 21733594) Gastric Cancer. 2015 Apr;18(2):227-38. (PMID: 24626858) J Clin Oncol. 2013 Nov 10;31(32):4105-14. (PMID: 24101053) Am J Surg Pathol. 2012 Feb;36(2):193-201. (PMID: 22251938) Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7. (PMID: 4026129) Cancer Treat Rev. 2022 Nov;110:102444. (PMID: 36108503) J Clin Oncol. 2009 Apr 1;27(10):1667-74. (PMID: 19255323) Cancer Discov. 2023 Jan 9;13(1):98-113. (PMID: 36264123) PLoS One. 2015 Dec 04;10(12):e0143468. (PMID: 26636767) J Clin Oncol. 2018 Nov 1;36(31):3101-3109. (PMID: 30156984) Lung Cancer. 2015 Feb;87(2):122-9. (PMID: 25534130) |
| Contributed Indexing: | Keywords: Amplification; Colorectal cancer; Fluorescence in situ hybridization; MET; Pathological features; Prognosis |
| Entry Date(s): | Date Created: 20240531 Latest Revision: 20240601 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11135301 |
| DOI: | 10.4240/wjgs.v16.i5.1395 |
| PMID: | 38817281 |
| Database: | MEDLINE |
| ISSN: | 1948-9366 |
|---|---|
| DOI: | 10.4240/wjgs.v16.i5.1395 |